178 related articles for article (PubMed ID: 11827989)
21. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.
Bontkes HJ; Kramer D; Ruizendaal JJ; Kueter EW; van Tendeloo VF; Meijer CJ; Hooijberg E
Gene Ther; 2007 Feb; 14(4):366-75. PubMed ID: 17036057
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
23. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.
Hsu AK; Kerr BM; Jones KL; Lock RB; Hart DN; Rice AM
Biol Blood Marrow Transplant; 2006 Aug; 12(8):855-67. PubMed ID: 16864056
[TBL] [Abstract][Full Text] [Related]
24. Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.
Rini B
Expert Opin Biol Ther; 2004 Nov; 4(11):1729-34. PubMed ID: 15500401
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo.
Zhang S; Zeng G; Wilkes DS; Reed GE; McGarry RC; Eble JN; Cheng L
Prostate; 2003 Jun; 55(4):292-8. PubMed ID: 12712408
[TBL] [Abstract][Full Text] [Related]
26. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell-based tumor immunotherapy.
Kadowaki N; Kitawaki T
Rinsho Ketsueki; 2009 May; 50(5):358-63. PubMed ID: 19483395
[No Abstract] [Full Text] [Related]
28. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
Essand M
Acta Oncol; 2005; 44(6):610-27. PubMed ID: 16165921
[No Abstract] [Full Text] [Related]
29. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
30. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
31. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
32. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
Michiels A; Breckpot K; Corthals J; Tuyaerts S; Bonehill A; Heirman C; Thielemans K; Aerts JL
Gene Ther; 2006 Jul; 13(13):1027-36. PubMed ID: 16511519
[TBL] [Abstract][Full Text] [Related]
33. [Cancer immunotherapy].
Vakkila J; Pihkala U
Duodecim; 1999; 115(7):785-94. PubMed ID: 11859512
[No Abstract] [Full Text] [Related]
34. Targeting the dendritic cell: the key to immunotherapy in cancer?
Faith A; Hawrylowicz CM
Clin Exp Immunol; 2005 Mar; 139(3):395-7. PubMed ID: 15730383
[No Abstract] [Full Text] [Related]
35. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP
Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355
[TBL] [Abstract][Full Text] [Related]
36. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Aalamian M; Tourkova IL; Chatta GS; Lilja H; Huland E; Huland H; Shurin GV; Shurin MR
J Urol; 2003 Nov; 170(5):2026-30. PubMed ID: 14532846
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK
Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228
[TBL] [Abstract][Full Text] [Related]
39. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
Qi SY; Wang M; Xu Y
Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
[TBL] [Abstract][Full Text] [Related]
40. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells.
Bontkes HJ; Kramer D; Ruizendaal JJ; Meijer CJ; Hooijberg E
Clin Immunol; 2008 Jun; 127(3):375-84. PubMed ID: 18358784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
